Overall, these results demonstrate that Prss56 inactivation rescues axial elongation/myopia resulting from EGR1 deficiency, and thereby establish PRSS56 as a potential therapeutic target for interventions aimed at preventing myopia. This evidence concerns the gene PRSS56 and myopia.